# CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

> **NCT07022964** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing GoBroad Hospital** · enrollment: 36 (estimated)

## Conditions studied

- T-Cell Non-Hodgkin Lymphoma
- T-cell Lymphoma (PTCL and CTCL)

## Interventions

- **DRUG:** CD5 CAR-T cells infusion

## Key facts

- **NCT ID:** NCT07022964
- **Lead sponsor:** Beijing GoBroad Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07022964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07022964, "CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07022964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*